Aliom Trading Pty Ltd

Status: Registered
Current name since: 1st May 2009
Name in the ASICs register: Aliom Trading Pty Ltd
Australian Company Number: 122140587
Australian Business Number: 31122140587
Registration date: 11th October 2006
Type: Australian proprietary company
Class: Limited by Shares
Subclass: Proprietary other
last updated


Aliom Trading Pty Ltd is a limited by shares Australian proprietary company. Located at NSW 2000 since 2006-12-01 the company is, as the updated on 2012-02-27 ABN database shows, registered. The company has been registered for Goods & Services Tax since 2006-12-01. Known company numbers for Aliom Trading Pty Ltd are as follows: ACN - 122140587, Australian Business Number - 31122140587. Aliom Trading Pty Ltd has been the company name since 2009-05-01. Their official company name changed on 2006-12-01 to Fusion Derivatives Pty Ltd. The company had used this name up until 2009-05-01. We found 0 trademarks that reference this company.


Details for ABN 31122140587

Type: Australian Private Company

ABN Status

Status From To
Active 1st December 2006 current

Main Name

Name From To
Aliom Trading Pty Ltd 1st May 2009 current
Fusion Derivatives Pty Ltd 1st December 2006 1st May 2009

Main Location

Location From To
NSW 2000 1st December 2006 current

Goods & Services Tax (GST)

Status From To
Registered 1st December 2006 current


Find company

NSW 2000 Location

2016 © - ABN Lookup, ACN, ABR, ABN Search. All rights reserved.
Contact us:
Terms of Use and Privacy Policy

Contains public sector information licensed under the Creative Commons Attribution 3.0 Australia licence. Material on this website was obtained from publicly-accessible databases and is attributed to ©Commonwealth of Australia 2015 (, and, ©Intellectual Property Government Open Data 2015, ©ASIC - Company Register. While we try to make the information as precise and up-to-date as possible, we are aware the datasets are not always error-free. will not take responsibility for any errors in the databases. The material provided should be treated as a starting point of more in-depth research, not as fact.